A Diagnostics Industry Roundtable: Where is Growth?
Executive Summary
An unprecedented wave of consolidations has everyone in diagnostics pondering what's next. Four top industry executives discuss the future of consolidation, the need for broader product lines to attract large-volume buyers, and the need to eliminate excess capacity from the system. New product opportunities exist, but the high cost of R&D will likely force more collaborations, particularly with medical device and drug companies.
You may also be interested in...
Dade Behring's Recap Plans
For more than a year, Dade Behring has been wading through a financial morass that is likely to lead to bankruptcy, a sale of assets, or a reorganization of capital structure. As concerns mount about its long-term prospects, Dade Behring and its lenders are seeking to restructure the company's burdensome long-term debt. While stubborn lenders have been unwilling to accept less than a near-to-full return on their investment, several events this spring seem to be motivating them to be more flexible.
As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance
Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.
ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach
The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahorta, has resigned from the role at the association after the company breached the ABPI Code of Practice.